Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › UBT251 phase 2 (T2D)

UBT251 phase 2 (T2D)

UBT251 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
UBT251
Population
t2d
Phase
2
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
UBT251 2.0 mgt2d china24———−2.2 vs −0.7——————verified
UBT251 6.0 mgt2d china24———−2.1 vs −0.7——————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (2)
  • UBT251 2.0 mg · hba1c · Results
    LSM change in HbA1c
  • UBT251 6.0 mg · hba1c · Results
    LSM change in HbA1c

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.